Biomarker Testing Market Size, Share, Biomarker Type, Disease Area, End-User and Regional Forecast, 2026–2035

Biomarker Testing Market Size & Forecast 2035

The global biomarker testing market was valued at USD 98.43 billion in 2025 and is forecast to reach USD 284.16 billion by 2035, expanding at a CAGR of 11.2% during 2026-2035. Biomarker testing measures biological characteristics in tissue, blood, cerebrospinal fluid, urine or other specimens to detect disease, classify patients, estimate prognosis, predict treatment response or monitor biological change. The market includes commercial assays, reagents and consumables, laboratory testing services, instrument-linked test revenue, companion diagnostics, analytical software and biomarker-testing services used in clinical trials.

The scope excludes drug revenue, general laboratory testing without a defined biomarker purpose, discovery-stage intellectual property that has not entered a testing workflow, and broad sequencing revenue unrelated to biomarker analysis. This boundary matters because the value of a biomarker can otherwise be counted in research, diagnostics and therapeutics at the same time.

The market is moving from single-analyte testing toward multiplex and multi-omic evidence. Oncology remains the largest commercial application, but blood-based Alzheimer’s testing, cardiometabolic risk assessment, immune profiling and pharmacodynamic monitoring are widening the addressable base. Commercial success depends on more than analytical accuracy: tests must fit clinical workflows, produce actionable results, obtain regulatory authorization where required and secure reimbursement or pharmaceutical sponsorship.

Key Highlights

• The market is forecast to increase from USD 98.43 billion in 2025 to USD 284.16 billion in 2035, creating USD 185.73 billion in incremental annual revenue.
• Tumor biomarker testing led the 2025 technology mix because targeted therapies and immunotherapies increasingly require molecular or protein-based patient selection.
• Diagnostic biomarkers represented the largest biomarker category, while predictive testing is gaining share through companion diagnostics and therapy-response selection.
• Pharmaceutical and biotechnology companies formed the largest end-user group through patient stratification, translational research, trial enrollment and treatment-response monitoring.
• North America held the leading regional share in 2025; Asia-Pacific is positioned for the strongest expansion as sequencing capacity and precision-medicine programs scale.
• Blood-based testing is reducing dependence on tissue, cerebrospinal-fluid collection and imaging in selected use cases, but positive results still require indication-specific clinical interpretation.
• Reimbursement, sample quality, threshold standardization, data interpretation and clinical utility remain the principal conversion barriers.

Market Dynamics

Targeted Therapy Makes Testing a Treatment Gateway

Many oncology medicines can be prescribed only after a qualifying alteration, protein expression level or genomic signature has been established. This makes the biomarker test part of the treatment pathway rather than an optional diagnostic add-on. Liquid biopsy widens access when tissue is unavailable or repeat sampling is clinically difficult, while tissue testing remains important for morphology, spatial context and confirmatory analysis.

The strongest commercial models coordinate the drug and test programs early. Diagnostic developers need locked assay designs, clinical cutoffs, manufacturing readiness and regulatory evidence in time for therapeutic submission. Delayed test availability can restrict treatment access and reduce the commercial reach of both partners.

Neurology Opens a High-Volume Blood-Testing Opportunity

Blood biomarkers such as phosphorylated tau are moving Alzheimer’s assessment closer to routine laboratory workflows. In May 2026, Roche received a CE mark for its Elecsys pTau217 assay, designed to help rule in or rule out amyloid pathology using a blood sample. Such tests can help prioritize specialist referral and reduce unnecessary invasive or high-cost follow-up, but they must be used with clinical information and indication-specific pathways.

Neurology adoption will depend on physician education, cutoff consistency, access to confirmatory testing and reimbursement. Laboratories with installed automated immunoassay platforms may gain a deployment advantage because a new assay can be added without creating an entirely separate testing infrastructure.

Multi-Omics Expands Discovery but Raises Interpretation Burden

Genomics, proteomics, transcriptomics and metabolomics reveal different layers of disease biology. Combining them can improve patient stratification and uncover composite signatures that a single analyte would miss. Thermo Fisher’s 2026 collaboration with Singapore’s PRECISE-SG100K program illustrates how population-scale proteomics and longitudinal clinical information are being joined to identify translational biomarkers.

The commercial challenge is converting complex patterns into a stable result that clinicians can interpret. Assay drift, algorithm changes, population bias and inconsistent sample handling can weaken reproducibility. Vendors therefore need reference standards, transparent quality control and locked analytical pipelines.

Validation and Reimbursement Remain the Main Bottlenecks

Analytical validity shows whether a test measures the biomarker reliably. Clinical validity links the result to a disease state or outcome, while clinical utility demonstrates that using the test improves a decision or patient result. Payers and health systems increasingly demand evidence across all three layers. A technically strong assay can therefore remain underused when its effect on treatment choice, downstream cost or patient outcome is unclear.

Small developers face particular pressure because prospective trials, reference laboratories, regulatory submissions and market access work require substantial capital. Partnerships with pharmaceutical companies, academic networks and large laboratory providers can provide samples and commercial reach, but contract terms may limit geographic or indication freedom.

Regulatory and Data Rules Reshape Laboratory Strategy

Companion diagnostics require coordination between therapeutic and device review. Laboratories must also manage privacy, consent, cross-border genomic data transfer, cybersecurity and version control for interpretation software. Regulatory differences between centralized kits, laboratory-developed tests and research-use-only products influence launch timing and channel strategy.

Market Scope

Market Segmentation

By Test Type

Tumor testing led with 31% of 2025 revenue, equal to USD 30.51 billion. Its lead reflects genomic profiling, immunohistochemistry, liquid biopsy and companion diagnostic use across lung, breast, colorectal, prostate and other cancers.

Genomic testing represented 24%, or USD 23.62 billion, covering inherited and acquired variants used in risk assessment, diagnosis and treatment selection. Molecular testing held 20%, equal to USD 19.69 billion, including PCR, digital PCR and other nucleic-acid or protein-linked workflows. Next-generation sequencing-based tests accounted for 17%, or USD 16.73 billion, supported by multiplex panels and comprehensive profiling. Somatic testing contributed 8%, equal to USD 7.87 billion, focused on acquired alterations present in tumor or diseased tissue rather than inherited germline variants.

By Biomarker Type

Diagnostic biomarkers accounted for 42% of 2025 revenue, or USD 41.34 billion. Their broad use in disease detection, classification and differential diagnosis supports recurring clinical volume. Predictive biomarkers represented 33%, equal to USD 32.48 billion, as targeted therapy and immunotherapy programs use tests to identify likely responders or patients at higher toxicity risk. Prognostic biomarkers held 25%, or USD 24.61 billion, supporting assessment of disease course, recurrence and patient risk independent of a specific treatment.

Predictive testing is expected to gain share through companion diagnostics, but diagnostic biomarkers will remain the largest revenue category because they address a broader patient population and more disease areas.

By Application

Disease diagnostics generated 35% of 2025 revenue, equal to USD 34.45 billion. Drug discovery and development accounted for 26%, or USD 25.59 billion, including trial eligibility, pharmacodynamic testing and response monitoring. Personalized medicine represented 22%, equal to USD 21.65 billion, driven by treatment selection based on molecular characteristics.

Disease-risk assessment held 10%, or USD 9.84 billion, covering inherited susceptibility and validated risk signatures. Other applications contributed 7%, equal to USD 6.89 billion, including wellness-linked testing, recurrence monitoring and specialized research workflows not captured elsewhere.

By Disease Area

Oncology led with 44% of 2025 revenue, equal to USD 43.31 billion. Neurological disorders represented 16%, or USD 15.75 billion, supported by expanding Alzheimer’s and neurodegeneration research. Cardiovascular and metabolic diseases contributed 15%, equal to USD 14.76 billion. Immunological and inflammatory disorders held 11%, or USD 10.83 billion, while infectious diseases represented 8%, equal to USD 7.87 billion. Other disease areas accounted for 6%, or USD 5.91 billion.

By End User

Pharmaceutical and biotechnology companies generated 35% of 2025 revenue, or USD 34.45 billion. Biomarkers help these companies select trial participants, demonstrate target engagement and build evidence for differentiated treatment response.

Diagnostic laboratories held 30%, equal to USD 29.53 billion, reflecting centralized molecular testing, pathology and high-throughput reference services. Hospitals and specialty clinics represented 24%, or USD 23.62 billion, while academic and research institutes accounted for 11%, equal to USD 10.83 billion.

Regional and Country-Level Analysis

North America

North America led with 39% of 2025 revenue, equal to USD 38.39 billion. The United States represented 34% of the global market, or USD 33.47 billion, supported by high oncology-testing volumes, companion diagnostic approvals, clinical-trial density, advanced laboratory infrastructure and established molecular-diagnostics reimbursement pathways. Canada contributed 4%, equal to USD 3.94 billion, with the remaining regional revenue generated in Mexico and associated cross-border testing activity.

The commercial advantage is strongest where laboratories combine regulatory authorization, broad payer coverage and fast turnaround. Coverage gaps, prior authorization and evidence requirements still restrict access outside well-established oncology indications.

Europe

Europe accounted for 26% of global revenue, or USD 25.59 billion. Germany generated 6% of worldwide demand, equal to USD 5.91 billion; the United Kingdom held 5%, or USD 4.92 billion; and France contributed 4%, equal to USD 3.94 billion. National genomic medicine programs, university hospitals and coordinated cancer networks support testing, while country-level reimbursement and data rules create fragmented commercialization requirements.

The region has a strong opportunity in standardized blood-based neurology tests and companion diagnostics. Adoption depends on health-technology assessment, laboratory budgets and evidence that testing reduces invasive procedures or improves treatment allocation.

Asia-Pacific

Asia-Pacific represented 25% of 2025 revenue, equal to USD 24.61 billion, and is expected to expand fastest through 2035. China held 8% of global revenue, or USD 7.87 billion; Japan generated 6%, equal to USD 5.91 billion; India represented 4%, or USD 3.94 billion; and South Korea held 3%, equal to USD 2.95 billion.

China is scaling domestic sequencing and molecular-diagnostic capacity. Japan combines an advanced diagnostics market with coordinated drug and companion-test review. India is expanding private oncology and genomics services, though affordability and insurance coverage remain constraints. South Korea benefits from high hospital digitization and precision-oncology investment.

Latin America

Latin America held 6% of global revenue, equal to USD 5.91 billion. Brazil is the regional leader through private laboratory networks, cancer centers and clinical research. Mexico, Argentina, Chile and Colombia add urban demand, but imported consumables, currency exposure and unequal reimbursement limit access outside major cities.

Middle East and Africa

The Middle East and Africa accounted for 4%, or USD 3.94 billion. The United Arab Emirates and Saudi Arabia are investing in genomic medicine, biobanks and specialty oncology infrastructure. South Africa remains a significant research and reference-laboratory center. Commercial expansion requires local validation, workforce development and reliable cold-chain or sample-transport systems.

Competitive Landscape and Key Players

The market includes integrated diagnostics groups, sequencing and PCR companies, reference laboratories, liquid-biopsy specialists and biomarker-service providers. Competition centers on clinical evidence, assay menu, installed instrument base, sample requirements, turnaround time, regulatory status, payer coverage and pharmaceutical partnerships.

Key participants include Roche Diagnostics, Thermo Fisher Scientific, QIAGEN, Guardant Health, Abbott Laboratories, Bio-Rad Laboratories, Illumina, Labcorp, Quest Diagnostics, Quanterix, Agilent Technologies, Siemens Healthineers, Danaher operating companies, BGI Genomics and Q2 Solutions.

Roche Diagnostics

Roche combines automated immunoassay, molecular diagnostics, digital pathology, tissue diagnostics and companion diagnostic capabilities. Its Elecsys portfolio covers protein biomarkers across oncology, cardiology, infectious disease and neurology. The cobas platform supports molecular and genomic testing, while Ventana systems serve tissue-based biomarker analysis.

In May 2026, Roche received CE marking for the Elecsys pTau217 blood test for Alzheimer’s pathology. The assay can be deployed across Roche’s installed automated-instrument base in CE-mark markets, giving the company a distribution and workflow advantage. Roche’s competitive position also benefits from coordination between its pharmaceutical and diagnostics operations.

Thermo Fisher Scientific

Thermo Fisher supplies Ion Torrent sequencing, Applied Biosystems PCR systems, Olink proximity-extension assays, Orbitrap mass spectrometry, reagents, clinical research services and bioinformatics capabilities. Its portfolio spans discovery, validation, trial testing and selected clinical workflows.

The April 2026 PRECISE-SG100K collaboration combines Olink targeted proteomics with Orbitrap Astral discovery proteomics for a cohort exceeding 100,000 participants. Thermo Fisher reports annual revenue above USD 40 billion. Its breadth allows it to serve biomarker programs from sample preparation through analysis and pharmaceutical development.

QIAGEN N.V.

QIAGEN provides sample preparation, PCR, digital PCR, next-generation sequencing panels, bioinformatics and companion diagnostic development. Its therascreen assays are used to identify genetic alterations linked to targeted therapies, while QIAstat-Dx, QIAcuity and QIAGEN Digital Insights extend its reach across syndromic testing, quantification and interpretation.

The company’s competitive strength lies in connecting sample-to-insight workflows with pharmaceutical partnerships. It can develop a companion diagnostic alongside a therapy and then supply regulated kits and interpretation support across multiple regions. Its decentralized testing products also allow selected biomarker workflows to move beyond major reference laboratories.

Guardant Health

Guardant Health focuses on blood- and tissue-based precision oncology. Guardant360 CDx profiles circulating tumor DNA for advanced-cancer treatment selection; Guardant Reveal supports recurrence monitoring; and Shield addresses colorectal cancer screening. The company also supplies data and services to biopharmaceutical developers.

In June 2026, the FDA approved Guardant360 CDx as a companion diagnostic for zongertinib in HER2-mutant advanced non-small cell lung cancer. The company reported that the platform had reached 27 companion diagnostic indications globally and payer coverage representing more than 300 million lives. Its competitive position is based on liquid-biopsy evidence, regulatory approvals and a growing clinical-data asset.

Recent Developments

• August 2026 - Quest Diagnostics and Roche: Quest announced that it would offer Roche’s FDA-cleared pTau217 blood test for assessment of Alzheimer’s disease pathology, expanding access through a major U.S. laboratory network.
• June 2026 - Labcorp: Labcorp announced nationwide availability of ColoSense, an FDA-approved RNA-based at-home colorectal cancer screening test. The launch extends biomarker testing into non-invasive sample collection and population screening.
• June 11, 2026 - Guardant Health: The FDA approved Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim’s zongertinib in HER2-mutant advanced non-small cell lung cancer.
• May 12, 2026 - Roche: Roche received CE marking for Elecsys pTau217, a blood biomarker assay intended to help rule in or rule out amyloid pathology in people with cognitive symptoms.
• April 30, 2026 - Abbott: Abbott presented expanded clinical evidence across its cancer diagnostics portfolio at ASCO 2026, covering biomarker-linked screening, diagnosis and treatment-management applications.
• April 9, 2026 - Thermo Fisher Scientific and PRECISE: The organizations announced a population-scale proteomics collaboration for Singapore’s PRECISE-SG100K cohort, combining Olink assays and Orbitrap mass spectrometry to advance biomarker discovery and translation.

Strategic Takeaways

• Clinical utility is the commercial gate. Analytical performance attracts scientific interest, but adoption accelerates only when the result changes diagnosis, referral, treatment or monitoring.
• Drug-test co-development protects launch value. Companion diagnostics must be validated, manufactured and distributed when the linked therapy reaches the market.
• Blood-based neurology testing is a major expansion route. Automated pTau assays can shift part of Alzheimer’s assessment into routine laboratories and support more efficient specialist referral.
• Liquid biopsy improves access but does not remove tissue testing. Blood tests are valuable when tissue is limited or repeat measurement is needed; negative or uncertain findings may still require tissue assessment.
• Installed platforms influence adoption speed. Assays compatible with existing analyzers can enter laboratory menus faster and require less capital than new standalone systems.
• Multi-omics creates differentiation and data risk. Composite signatures may improve stratification, but reproducibility, algorithm governance and population bias require strict control.
• Reimbursement strategy must begin during validation. Evidence plans should address payer questions about patient outcomes, avoided procedures and total treatment cost before launch.

Why Purchase the Report?

• To visualize the global biomarker testing market segmentation based on test type, biomarker type, application, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of biomarker testing market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global biomarker testing market report would provide approximately 53 tables, 47 figures and 276 pages.

Target Audience

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies